Copyright © 2011 Costantine Albany et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011. View at Publisher · View at Google Scholar · View at PubMed
2. A. S. Perry, R. W. G. Watson, M. Lawler, and D. Hollywood, “The epigenome as a therapeutic target in prostate cancer,” Nature Reviews Urology, vol. 7, no. 12, pp. 668–680, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
3. L. C. Li, P. R. Carroll, and R. Dahiya, “Epigenetic changes in prostate cancer: implication for diagnosis and treatment,” Journal of the National Cancer Institute, vol. 97, no. 2, pp. 103–115, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
4. M. Manoharan, K. Ramachandran, M. S. Soloway, and R. Singal, “Epigenetic targets in the diagnosis and treatment of prostate cancer,” International Brazilian Journal of Urology, vol. 33, no. 1, pp. 11–18, 2007.
5. P. M. Das and R. Singal, “DNA methylation and cancer,” Journal of Clinical Oncology, vol. 22, no. 22, pp. 4632–4642, 2004. View at Publisher · View at Google Scholar · View at PubMed
6. D. Takai and P. A. Jones, “Comprehensive analysis of CpG islands in human chromosomes 21 and 22,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 6, pp. 3740–3745, 2002. View at Publisher · View at Google Scholar · View at PubMed
7. A. P. Bird, “CpG-rich islands and the function of DNA methylation,” Nature, vol. 321, no. 6067, pp. 209–213, 1986.
8. R. Singal and G. D. Ginder, “DNA methylation,” Blood, vol. 93, no. 12, pp. 4059–4070, 1999.
9. S. B. Baylin, “Tying it all together: Epigenetics, genetics, cell cycle, and cancer,” Science, vol. 277, no. 5334, pp. 1948–1949, 1997. View at Publisher · View at Google Scholar
10. A. Laayoun and S. S. Smith, “Methylation of slipped duplexes, snapbacks and cruciforms by human DNA(cytosine-5)methyltransferase,” Nucleic Acids Research, vol. 23, no. 9, pp. 1584–1589, 1995.
11. C. M. Wong, C. C.-L. Wong, Y.-L. Ng, S. L.-K. Au, F. C.-F. Ko, and I. O.-L. Ng, “Transcriptional repressive H3K9 and H3K27 methylations contribute to DNMT1-mediated DNA methylation recovery,” PLoS ONE, vol. 6, no. 2, article e16702, 2011. View at Publisher · View at Google Scholar · View at PubMed
12. S. Yegnasubramanian, J. Kowalski, M. L. Gonzalgo et al., “Hypermethylation of CpG islands in primary and metastatic human prostate cancer,” Cancer Research, vol. 64, no. 6, pp. 1975–1986, 2004. View at Publisher · View at Google Scholar
13. C. Jerónimo, R. Henrique, M. O. Hoque et al., “A quantitative promoter methylation profile of prostate cancer,” Clinical Cancer Research, vol. 10, no. 24, pp. 8472–8478, 2004. View at Publisher · View at Google Scholar · View at PubMed
14. R. Maruyama, S. Toyooka, K. O. Toyooka et al., “Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features,” Clinical Cancer Research, vol. 8, no. 2, pp. 514–519, 2002.
15. W. A. Schulz and J. Hatina, “Epigenetics of prostate cancer: beyond DNA methylation,” Journal of Cellular and Molecular Medicine, vol. 10, no. 1, pp. 100–125, 2006. View at Publisher · View at Google Scholar
16. W. G. Nelson, A. M. De Marzo, and W. B. Isaacs, “Prostate cancer,” New England Journal of Medicine, vol. 349, no. 4, pp. 366–381, 2003. View at Publisher · View at Google Scholar · View at PubMed
17. C. D. Chen, D. S. Welsbie, C. Tran et al., “Molecular determinants of resistance to antiandrogen therapy,” Nature Medicine, vol. 10, no. 1, pp. 33–39, 2004. View at Publisher · View at Google Scholar · View at PubMed
18. M. E. Taplin, “Androgen receptor: role and novel therapeutic prospects in prostate cancer,” Expert Review of Anticancer Therapy, vol. 8, no. 9, pp. 1495–1508, 2008. View at Publisher · View at Google Scholar · View at PubMed
19. T. Nakayama, M. Watanabe, H. Suzuki et al., “Epigenetic regulation of androgen receptor gene expression in human prostate cancers,” Laboratory Investigation, vol. 80, no. 12, pp. 1789–1796, 2000.
20. S. Bayraktar, “The mechanism of androgen deprivation and the androgen receptor,” The Open Prostate Cancer Journal, vol. 3, pp. 47–56, 2010.
21. G. L. Gravina, F. Marampon, M. D. Staso et al., “5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors,” Prostate, vol. 70, no. 11, pp. 1166–1178, 2010. View at Publisher · View at Google Scholar · View at PubMed
22. G. L. Gravina, C. Festuccia, D. Millimaggi et al., “Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells,” Prostate, vol. 68, no. 7, pp. 793–801, 2008. View at Publisher · View at Google Scholar · View at PubMed
23. A. S. Alva, N. M. Hahn, A. M. Aparicio, R. Singal, S. Yellapragada, and G. Sonpavde, “Hypomethylating agents for urologic cancers,” Future Oncology, vol. 7, no. 3, pp. 447–463, 2011. View at Publisher · View at Google Scholar · View at PubMed
24. M. F. Chen, W. C. Chen, Y. J. Chang, C. F. Wu, and C. T. Wu, “Role of DNA methyltransferase 1 in hormone-resistant prostate cancer,” Journal of Molecular Medicine, vol. 88, no. 9, pp. 953–962, 2010. View at Publisher · View at Google Scholar · View at PubMed
25. J. Z. Song, C. Stirzaker, J. Harrison, J. R. Melki, and S. J. Clark, “Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells,” Oncogene, vol. 21, no. 7, pp. 1048–1061, 2002. View at Publisher · View at Google Scholar
26. D. S. Millar, K. K. Ow, C. L. Paul, P. J. Russell, P. L. Molloy, and S. J. Clark, “Detailed methylation analysis of the glutathione S-transferase π (GSTP1) gene in prostate cancer,” Oncogene, vol. 18, no. 6, pp. 1313–1324, 1999.
27. M. Nakayama, C. J. Bennett, J. L. Hicks et al., “Hypermethylation of the human glutathione S-transferase-π gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection,” American Journal of Pathology, vol. 163, no. 3, pp. 923–933, 2003.
28. W. H. Lee, R. A. Morton, J. I. Epstein et al., “Cytidine methylation of regulatory sequences near the π-class glutathione S-transferase gene accompanies human prostatic carcinogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 24, pp. 11733–11737, 1994. View at Publisher · View at Google Scholar
29. R. Singal, J. Van Wert, and M. Bashambu, “Cytosine methylation represses glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells,” Cancer Research, vol. 61, no. 12, pp. 4820–4826, 2001.
30. J. Ellinger, P. J. Bastian, T. Jurgan et al., “CpG Island Hypermethylation at Multiple Gene Sites in Diagnosis and Prognosis of Prostate Cancer,” Urology, vol. 71, no. 1, pp. 161–167, 2008. View at Publisher · View at Google Scholar · View at PubMed
31. M. Nakayama, M. L. Gonzalgo, S. Yegnasubramanian, X. Lin, A. M. De Marzo, and W. G. Nelson, “GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer,” Journal of Cellular Biochemistry, vol. 91, no. 3, pp. 540–552, 2004. View at Publisher · View at Google Scholar · View at PubMed
32. M. Rouprêt, V. Hupertan, J. W. F. Catto et al., “Promoter hypermethylation in circulating blood cells identifies prostate cancer progression,” International Journal of Cancer, vol. 122, no. 4, pp. 952–956, 2008. View at Publisher · View at Google Scholar · View at PubMed
33. M. J. Bello, M. E. Alonso, C. Aminoso et al., “Hypermethylation of the DNA repair gene MGMT: association with TP53 G:C to A:T transitions in a series of 469 nervous system tumors,” Mutation Research, vol. 554, no. 1-2, pp. 23–32, 2004. View at Publisher · View at Google Scholar · View at PubMed
34. S. Sidhu, J. S. Deep, R. C. Sobti, V. L. Sharma, and H. Thakur, “Methylation pattern of MGMT gene in relation to age, smoking, drinking and dietary habits as epigenetic biomarker in prostate cancer patients,” Genetic Engineering and Biotechnology Journal, 2010.
35. L. Richiardi, V. Fiano, L. Vizzini et al., “Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients,” Journal of Clinical Oncology, vol. 27, no. 19, pp. 3161–3168, 2009. View at Publisher · View at Google Scholar · View at PubMed
36. S. B. Baylin and J. E. Ohm, “Epigenetic gene silencing in cancer - A mechanism for early oncogenic pathway addiction?” Nature Reviews Cancer, vol. 6, no. 2, pp. 107–116, 2006. View at Publisher · View at Google Scholar · View at PubMed
37. C. Jerónimo, R. Henrique, M. O. Hoque et al., “Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker,” Clinical Cancer Research, vol. 10, no. 12, pp. 4010–4014, 2004.
38. D. K. Vanaja, K. V. Ballman, B. W. Morlan et al., “PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer,” Clinical Cancer Research, vol. 12, no. 4, pp. 1128–1136, 2006. View at Publisher · View at Google Scholar · View at PubMed
39. M. Frommer, L. E. McDonald, D. S. Millar et al., “A genomic sequencing protocol that yields a positive display of 5- methylcytosine residues in individual DNA strands,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 5, pp. 1827–1831, 1992.
40. J. Zhang, L. Liu, and G. P. Pfeifer, “Methylation of the retinoid response gene TIG1 in prostate cancer correlates with methylation of the retinoic acid receptor beta gene,” Oncogene, vol. 23, no. 12, pp. 2241–2249, 2004. View at Publisher · View at Google Scholar · View at PubMed
41. R. Dammann, U. Schagdarsurengin, C. Seidel et al., “The tumor suppressor RASSF1A in human carcinogenesis: an update,” Histology and Histopathology, vol. 20, no. 2, pp. 645–663, 2005.
42. J. S. Ross, H. L. Figge, H. X. Bui et al., “E-cadherin expression in prostatic carcinoma biopsies: correlation with tumor grade, DNA content, pathologic stage, and clinical outcome,” Modern Pathology, vol. 7, no. 8, pp. 835–841, 1994.
43. P. J. M. Richmond, A. J. Karayiannakis, A. Nagafuchi, A. V. Kaisary, and M. Pignatelli, “Aberrant E-cadherin and α-catenin expression in prostate cancer: correlation with patient survival,” Cancer Research, vol. 57, no. 15, pp. 3189–3193, 1997.
44. J. R. Graff, J. G. Herman, R. G. Lapidus et al., “E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas,” Cancer Research, vol. 55, no. 22, pp. 5195–5199, 1995.
45. M. Lombaerts, T. Van Wezel, K. Philippo et al., “E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-tomesenchymal transition in breast cancer cell lines,” British Journal of Cancer, vol. 94, no. 5, pp. 661–671, 2006. View at Publisher · View at Google Scholar · View at PubMed
46. W. Lou, D. Krill, R. Dhir et al., “Methylation of the CD44 metastasis suppressor gene in human prostate cancer,” Cancer Research, vol. 59, no. 10, pp. 2329–2331, 1999.
47. K. Woodson, R. Hayes, L. Wideroff, L. Villaruz, and J. Tangrea, “Hypermethylation of GSTP1, CD44, and E-cadherin genes in prostate cancer among US blacks and whites,” Prostate, vol. 55, no. 3, pp. 199–205, 2003. View at Publisher · View at Google Scholar · View at PubMed
48. A. Padar, U. G. Sathyanarayana, M. Suzuki et al., “Inactivation of Cyclin D2 Gene in Prostate Cancers by Aberrant Promoter Methylation,” Clinical Cancer Research, vol. 9, no. 13, pp. 4730–4734, 2003.
49. R. Henrique, V. L. Costa, N. Cerveira et al., “Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer,” Journal of Molecular Medicine, vol. 84, no. 11, pp. 911–918, 2006. View at Publisher · View at Google Scholar · View at PubMed
50. O. Mortusewicz, L. Schermelleh, J. Walter, M. C. Cardoso, and H. Leonhardt, “Recruitment of DNA methyltransferase I to DNA repair sites,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 25, pp. 8905–8909, 2005. View at Publisher · View at Google Scholar · View at PubMed
51. K. Ramachandran, G. Gopisetty, E. Gordian et al., “Methylation-mediated repression of GADD45α in prostate cancer and its role as a potential therapeutic target,” Cancer Research, vol. 69, no. 4, pp. 1527–1535, 2009. View at Publisher · View at Google Scholar · View at PubMed
52. B. B. McConnell and P. M. Vertino, “TMS1/ASC: the cancer connection,” Apoptosis, vol. 9, no. 1, pp. 5–18, 2004. View at Publisher · View at Google Scholar · View at PubMed
53. B. B. McConnell and P. M. Vertino, “Activation of a caspase-9-mediated apoptotic pathway by subcellular redistribution of the novel caspase recruitment domain protein TMS1,” Cancer Research, vol. 60, no. 22, pp. 6243–6247, 2000.
54. P. M. Das, K. Ramachandran, J. VanWert et al., “Methylation mediated silencing of TMS1/ASC gene in prostate cancer,” Molecular Cancer, vol. 5, article 28, 2006. View at Publisher · View at Google Scholar · View at PubMed
55. M. T. Bedford and P. D. Van Helden, “Hypomethylation of DNA in pathological conditions of the human prostate,” Cancer Research, vol. 47, no. 20, pp. 5274–5276, 1987.
56. W. G. Nelson, S. Yegnasubramanian, A. T. Agoston et al., “Abnormal DNA methylation, epigenetics, and prostate cancer,” Frontiers in Bioscience, vol. 12, pp. 4254–4266, 2007. View at Publisher · View at Google Scholar
57. S. Yegnasubramanian, M. C. Haffner, Y. Zhang et al., “DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity,” Cancer Research, vol. 68, no. 21, pp. 8954–8967, 2008. View at Publisher · View at Google Scholar · View at PubMed
58. S. Santourlidis, A. Florl, R. Ackermann, H. C. Wirtz, and W. A. Schulz, “High frequency of alterations in DNA methylation in adenocarcinoma of the prostate,” Prostate, vol. 39, no. 3, pp. 166–174, 1999. View at Publisher · View at Google Scholar
59. B. Gurel, T. Iwata, C. M. Koh et al., “Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis,” Modern Pathology, vol. 21, no. 9, pp. 1156–1167, 2008. View at Publisher · View at Google Scholar · View at PubMed
60. D. Bernard, A. Pourtier-Manzanedo, J. Gil, and D. H. Beach, “Myc confers androgen-independent prostate cancer cell growth,” Journal of Clinical Investigation, vol. 112, no. 11, pp. 1724–1731, 2003. View at Publisher · View at Google Scholar
61. P. J. van Veldhuizen, R. Sadasivan, R. Cherian, and A. Wyatt, “Urokinase-type plasminogen activator expression in human prostate carcinomas,” American Journal of the Medical Sciences, vol. 312, no. 1, pp. 8–11, 1996. View at Publisher · View at Google Scholar
62. M. A. Helenius, O. R. Saramäki, M. J. Linja, T. L. J. Tammela, and T. Visakorpi, “Amplification of urokinase gene in prostate cancer,” Cancer Research, vol. 61, no. 14, pp. 5340–5344, 2001.
63. W. A. Schulz, J. P. Elo, A. R. Florl et al., “Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma,” Genes Chromosomes and Cancer, vol. 35, no. 1, pp. 58–65, 2002. View at Publisher · View at Google Scholar · View at PubMed
64. J. R. Dobosy and E. U. Selker, “Emerging connections between DNA methylation and histone acetylation,” Cellular and Molecular Life Sciences, vol. 58, no. 5-6, pp. 721–727, 2001.
65. M. H. Kuo and C. D. Allis, “Roles of histone acetyltransferases and deacetylases in gene regulation,” BioEssays, vol. 20, no. 8, pp. 615–626, 1998. View at Publisher · View at Google Scholar
66. M. Esteller, “Cancer epigenomics: DNA methylomes and histone-modification maps,” Nature Reviews Genetics, vol. 8, no. 4, pp. 286–298, 2007. View at Publisher · View at Google Scholar · View at PubMed
67. C. Martin and Y. Zhang, “The diverse functions of histone lysine methylation,” Nature Reviews Molecular Cell Biology, vol. 6, no. 11, pp. 838–849, 2005. View at Publisher · View at Google Scholar · View at PubMed
68. T. Kouzarides, “Chromatin modifications and their function,” Cell, vol. 128, no. 4, pp. 693–705, 2007. View at Publisher · View at Google Scholar · View at PubMed
69. K. Yamane, C. Toumazou, Y. I. Tsukada et al., “JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor,” Cell, vol. 125, no. 3, pp. 483–495, 2006. View at Publisher · View at Google Scholar · View at PubMed
70. Q. Wang, W. Li, Y. Zhang et al., “Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer,” Cell, vol. 138, no. 2, pp. 245–256, 2009. View at Publisher · View at Google Scholar · View at PubMed
71. J. H. van Ree, K. B. Jeganathan, L. Malureanu, and J. M. Van Deursen, “Overexpression of the E2 ubiquitin-conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation,” Journal of Cell Biology, vol. 188, no. 1, pp. 83–100, 2010. View at Publisher · View at Google Scholar · View at PubMed
72. J. Ai, Y. Wang, J. A. Dar et al., “HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer,” Molecular Endocrinology, vol. 23, no. 12, pp. 1963–1972, 2009. View at Publisher · View at Google Scholar · View at PubMed
73. C. W. Gregory, B. He, R. T. Johnson et al., “A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy,” Cancer Research, vol. 61, no. 11, pp. 4315–4319, 2001.
74. S. A. Onate, S. Y. Tsai, M. J. Tsai, and B. W. O'Malley, “Sequence and characterization of a coactivator for the steroid hormone receptor superfamily,” Science, vol. 270, no. 5240, pp. 1354–1357, 1995.
75. M. C. Louie, H. Q. Yang, A. H. Ma et al., “Androgen-induced recruitment of RNA polymerase II to a nuclear receptor-p160 coactivator complex,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 5, pp. 2226–2230, 2003. View at Publisher · View at Google Scholar · View at PubMed
76. D. B. Seligson, S. Horvath, T. Shi et al., “Global histone modification patterns predict risk of prostate cancer recurrence,” Nature, vol. 435, no. 7046, pp. 1262–1266, 2005. View at Publisher · View at Google Scholar · View at PubMed
77. J. Ellinger, P. Kahl, J. Von Der Gathen et al., “Global levels of histone modifications predict prostate cancer recurrence,” Prostate, vol. 70, no. 1, pp. 61–69, 2010. View at Publisher · View at Google Scholar · View at PubMed
78. T. Bianco-Miotto, K. Chiam, G. Buchanan et al., “Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development,” Cancer Epidemiology Biomarkers and Prevention, vol. 19, no. 10, pp. 2611–2622, 2010. View at Publisher · View at Google Scholar · View at PubMed
79. L. X. Zhou, T. Li, Y. R. Huang, J. J. Sha, P. Sun, and D. Li, “Application of histone modification in the risk prediction of the biochemical recurrence after radical prostatectomy,” Asian Journal of Andrology, vol. 12, no. 2, pp. 171–179, 2010. View at Publisher · View at Google Scholar · View at PubMed
80. L. A. Mathews, F. Crea, and W. L. Farrar, “Epigenetic gene regulation in stem cells and correlation to cancer,” Differentiation, vol. 78, no. 1, pp. 1–17, 2009. View at Publisher · View at Google Scholar · View at PubMed
81. S. Varambally, S. M. Dhanasekaran, M. Zhou et al., “The polycomb group protein EZH2 is involved in progression of prostate cancer,” Nature, vol. 419, no. 6907, pp. 624–629, 2002. View at Publisher · View at Google Scholar · View at PubMed
82. Y. Xiao, “Enhancer of zeste homolog 2: a potential target for tumor therapy,” International Journal of Biochemistry and Cell Biology, vol. 43, no. 4, pp. 474–477, 2011. View at Publisher · View at Google Scholar · View at PubMed
83. D. Xie, C. Gore, J. Liu et al., “Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 6, pp. 2485–2490, 2010. View at Publisher · View at Google Scholar · View at PubMed
84. H. Chen, S. Toyooka, A. F. Gazdar, and J. T. Hsieh, “Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines,” Journal of Biological Chemistry, vol. 278, no. 5, pp. 3121–3130, 2003. View at Publisher · View at Google Scholar · View at PubMed
85. J. Min, A. Zaslavsky, G. Fedele et al., “An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor -kappaB,” Nature Medicine, vol. 16, no. 3, pp. 286–294, 2010. View at Publisher · View at Google Scholar · View at PubMed
86. J. Yu, Q. Cao, J. Yu et al., “The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer,” Oncogene, vol. 29, no. 39, pp. 5370–5380, 2010. View at Publisher · View at Google Scholar · View at PubMed
87. S. A. Tomlins, B. Laxman, S. M. Dhanasekaran et al., “Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer,” Nature, vol. 448, no. 7153, pp. 595–599, 2007. View at Publisher · View at Google Scholar · View at PubMed
88. P. Kunderfranco, M. Mello-Grand, R. Cangemi et al., “ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer,” PloS one, vol. 5, no. 5, article e10547, 2010. View at Publisher · View at Google Scholar · View at PubMed
89. S. Cottrell, K. Jung, G. Kristiansen et al., “Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis,” Journal of Urology, vol. 177, no. 5, pp. 1753–1758, 2007. View at Publisher · View at Google Scholar · View at PubMed
90. E. Rosenbaum, M. O. Hoque, Y. Cohen et al., “Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy,” Clinical Cancer Research, vol. 11, no. 23, pp. 8321–8325, 2005. View at Publisher · View at Google Scholar · View at PubMed
91. M. O. Hoque, “DNA methylation changes in prostate cancer: current developments and future clinical implementation,” Expert Review of Molecular Diagnostics, vol. 9, no. 3, pp. 243–257, 2009. View at Publisher · View at Google Scholar · View at PubMed
92. W. Weichert, A. Röske, V. Gekeler et al., “Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy,” British Journal of Cancer, vol. 98, no. 3, pp. 604–610, 2008. View at Publisher · View at Google Scholar · View at PubMed
93. Y. Song, M. Shiota, S. Tamiya, K. Kuroiwa, S. Naito, and M. Tsuneyoshi, “The significance of strong histone deacetylase 1 expression in the progression of prostate cancer,” Histopathology, vol. 58, no. 5, pp. 773–780, 2011. View at Publisher · View at Google Scholar · View at PubMed
94. J. Yu, J. Yu, D. R. Rhodes et al., “A polycomb repression signature in metastatic prostate cancer predicts cancer outcome,” Cancer Research, vol. 67, no. 22, pp. 10657–10663, 2007. View at Publisher · View at Google Scholar · View at PubMed
95. C. Festuccia, G. L. Gravina, A. M. D'Alessandro et al., “Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models,” Endocrine-Related Cancer, vol. 16, no. 2, pp. 401–413, 2009. View at Publisher · View at Google Scholar · View at PubMed
96. P. Frost, J. L. Abbruzzese, B. Hunt, D. Lee, and M. Ellis, “Synergistic cytotoxicity using 2'-deoxy-5-azacytidine and cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells,” Cancer Research, vol. 50, no. 15, pp. 4572–4577, 1990.
97. G. Sonpavde, A. M. Aparicio, F. Zhan, et al., “Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer,” Urologic Oncology, vol. 29, no. 6, pp. 682–689, 2011. View at Publisher · View at Google Scholar · View at PubMed
98. M. A. Rudek, M. Zhao, P. He et al., “Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies,” Journal of Clinical Oncology, vol. 23, no. 17, pp. 3906–3911, 2005. View at Publisher · View at Google Scholar · View at PubMed
99. L. M. Butler, D. B. Agus, H. I. Scher et al., “Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo,” Cancer Research, vol. 60, no. 18, pp. 5165–5170, 2000.
100. V. Sandor, A. Senderowicz, S. Mertins et al., “P21-dependent G1 arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228,” British Journal of Cancer, vol. 83, no. 6, pp. 817–825, 2000.
101. O. W. Rokhlin, A. F. Taghiyev, N. V. Guseva et al., “Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP,” Oncogene, vol. 24, no. 45, pp. 6773–6784, 2005. View at Publisher · View at Google Scholar · View at PubMed
102. X. M. Liu, A. Gomez-Pinillos, X. Liu, E. M. Johnson, and A. C. Ferrari, “Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic purα-mediated decrease in androgen receptor levels,” Prostate, vol. 70, no. 2, pp. 179–189, 2010. View at Publisher · View at Google Scholar · View at PubMed
103. L. Chen, S. Meng, H. Wang et al., “Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824,” Molecular Cancer Therapeutics, vol. 4, no. 9, pp. 1311–1319, 2005. View at Publisher · View at Google Scholar · View at PubMed
104. C. S. Chen, Y. C. Wang, H. C. Yang et al., “Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation,” Cancer Research, vol. 67, no. 11, pp. 5318–5327, 2007. View at Publisher · View at Google Scholar · View at PubMed
105. D. L. Marrocco, W. D. Tilley, T. Bianco-Miotto et al., “Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation,” Molecular Cancer Therapeutics, vol. 6, no. 1, pp. 51–60, 2007. View at Publisher · View at Google Scholar · View at PubMed
106. D. Bradley, D. Rathkopf, R. Dunn et al., “Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862),” Cancer, vol. 115, no. 23, pp. 5541–5549, 2009. View at Publisher · View at Google Scholar · View at PubMed
107. L. R. Molife, G. Attard, P. C. Fong et al., “Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC),” Annals of Oncology, vol. 21, no. 1, pp. 109–113, 2010.
108. D. Rathkopf, B. Y. Wong, R. W. Ross et al., “A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer,” Cancer Chemotherapy and Pharmacology, vol. 66, no. 1, pp. 181–189, 2010. View at Publisher · View at Google Scholar · View at PubMed
109. M. J. Peart, G. K. Smyth, R. K. Van Laar et al., “Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 10, pp. 3697–3702, 2005. View at Publisher · View at Google Scholar · View at PubMed